Skip Navigation


Human Reproduction Update Advance Access originally published online on March 14, 2008
Human Reproduction Update 2008 14(3):259-274; doi:10.1093/humupd/dmn006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
14/3/259    most recent
dmn006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tropeano, G.
Right arrow Articles by Scambia, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tropeano, G.
Right arrow Articles by Scambia, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Non-surgical management of uterine fibroids

Giovanna Tropeano1, Sonia Amoroso and Giovanni Scambia

Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy

1 Correspondence address. E-mail: giovannatropeano{at}tiscali.it

BACKGROUND: Efforts to develop alternatives to surgery for management of symptomatic uterine fibroids have provided new techniques and new medications. This review summarizes the existing literature on uterine artery embolization (UAE) and investigational studies on four newer approaches. METHODS: PubMed, Cochrane and Embase were searched up to December 2007. Studies reporting side-effects and complications and presenting numerical data on at least one outcome measure were included. RESULTS: Case studies report 50–60% reduction in fibroid size and 85–95% relief of symptoms following UAE. The largest of these studies reported an in-hospital complication rate of 2.7% (90 of 3041 patients) and a post-discharge complication rate of 26% (710 of 2729 patients). Eight studies compared UAE with conventional surgery. Best evidence suggested that UAE offered shorter hospital stays (1–2 days UAE versus 5–5.8 days surgery, 3 randomized controlled trials (RCTs)) and recovery times (9.5–28 days UAE versus 36.2–63 days surgery, 3 RCTs) and similar major complication rates (2–15% UAE versus 2.7–20% surgery, 3 RCTs). Four studies analysing cost-effectiveness found UAE more cost-effective than surgery. There is insufficient evidence regarding fertility and pregnancy outcome after UAE. Five feasibility studies after transvaginal temporary uterine artery occlusion in 75 women showed a 40–50% reduction in fibroid volume and two early studies using magnetic resonance guided–focused ultrasound showed symptom relief at 6 months in 71% of 109 women. Two small RCTs assessing mifepristone and asoprisnil showed promising results. CONCLUSIONS: Good quality evidence supports the safety and effectiveness of UAE for women with symptomatic fibroids. The current available data are insufficient to routinely offer UAE to women who wish to preserve or enhance their fertility. Newer treatments are still investigational.

Key words: embolization / fibroid / focused ultrasound / medical therapy

Received on September 14, 2007; revised January 17, 2008; accepted on January 31, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.